The study aim was to evaluate whether the 
Mineralocorticoid Receptors (MR) antagonist eplerenone, 
effects circulating microparticles originated from apoptotic 
and activated endothelial cells (EMP) in Chronic Heart 
Failure (CHF) patients. 
Methods: The study population consisted of 152 
consecutive patients with CHF who underwent 
angiography or PCI between April 2010 and June 2014, 
and post-myocardial infarction subjects. All subjects 
enrolled in the study were divided into two cohorts: 
eplerenone treated (n=45) or placebo (n=107) for 52 
weeks. Patients were treated with optimal dose of 
eplerenone (25-50 mg daily) adjusted to plasma potassium. 
All biomarkers were determined at the beginning 
(baseline) and at the termination of the study. Endothelial
derived Microparticles (EMPs) were phenotyped by flow 
cytometry using a High-Definition Fluorescence Activated 
Cell Sorter. 
Results: At baseline, there was not difference in EMPs 
between groups. Eplerenone treatment reduced EMPs 
(CD144+/ CD31+/annexin V+ and CD31+/annexin V+) 
when compared with placebo. But activated CD62E+ EMP 
numbers were significantly increased by 24.3%.